Diarylquinolines (DARQs) is a chemical class of drugs that treat tuberculosis, e.g. bedaquiline. The drug targets the subunit c of mycobacterial ATP synthase, inhibiting the enzyme so mycobacterium tuberculosis cannot synthesise ATP. This effectively kills the bacteria. As of 2014, the only licensed indication of the drug bedaquiline is in the treatment of multi-drug-resistant tuberculosis, primarily due to concerns about safety.